To develop an intramuscular inactivated whole virus vaccine from early product selection through a phase i clinical trial to induce protection against EV D68 induced AFM.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00037
- Awardee
-
Intravacc B.V. UEI RY3NEWMNZA63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,042,149
Award facts
- Opportunity
-
- 2020 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20201 · Posted Dec 11, 2019
- HHS-NIH-NIAID-BAA2020-1: Research Area 002, Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis Associated with Enterovirus D68 Award Notice · Posted Aug 20, 2020
- 2020 NIAID Omnibus Broad Agency Announcement Solicitation · Posted Jan 3, 2020
- Contract value 98% obligated
-
- $9,042,149.30 Current, with exercised options
- $9,261,662.30 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ12 General Science And Technology R&D Services; General Science And Technology; Applied Research
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- 2511 The Hague, Netherlands
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$964,757 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | -$146,113 | |
| Funding Only Action | $1,004,130 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,085,889 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $194,459 | |
| Novation Agreement | $0 | |
| Exercise an Option | $5,031,575 | |
| Original award | $2,836,966 |
Show all 16
About this award
The National Institute of Allergy and Infectious Diseases awarded a $9.26 million definitive cost-no-fee contract to Intravacc B.V. on September 1, 2020, to develop an intramuscular inactivated whole virus vaccine from early product selection through a Phase I clinical trial to induce protection against Enterovirus D68-induced acute flaccid myelitis.
No set-aside was used. Place of performance is The Hague, Netherlands. The contract's ultimate completion date is May 31, 2026.
Under Service Contract Inventory reporting, the contract has invoiced $1.4 million to $1.6 million annually across FY2021–FY2025. Labor footprint ranged from 2.9 to 4.3 FTEs, with contractor hours between 7,252 and 8,850 across those years. Derived government-paid hourly rates remained roughly flat, ranging from $167.67 to $226.56 per hour. In FY2025, the most recent reported period, the contract operated at 2.9 FTEs with no subcontractors; Intravacc self-performed all reported hours.
Quick answers
Who was awarded contract 75N93020C00037?
75N93020C00037 was awarded to Intravacc B.V. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2020.
How much is contract 75N93020C00037 worth?
The government has obligated $9,042,149 on 75N93020C00037. Its potential value, with all options, is $9,261,662.
Was contract 75N93020C00037 competed?
The extent of competition for 75N93020C00037 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award